With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.29726-60-1,3-Methyl-1,2,3,4-tetrahydroisoquinoline,as a common compound, the synthetic route is as follows.,29726-60-1
Example 141 : N-tert-Butyl-2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1 -oxo-2,3- dihydro-1 H-isoindol-2-yl)acetamide (2628) (2629) A stirred solution of 2-(6-{5-chloro-2-[(oxan-4-yl)amino]pyrimidin-4-yl}-1-oxo-2,3-dihydro-1 H- isoindol-2-yl)acetic acid (Example 1 , 60 mg, 0.10 mmol, 70 % pure) in anhydrous 1 ,4- dioxane/DMF (3 : 1 , 1.5 mL) under nitrogen was treated with DIPEA (36 muIota_, 0.21 mmol), HBTU (81 mg, 0.21 mmol) and then tert-butylamine (17 muIota_, 0.16 mmol). The reaction was stirred for 4 days at room temperature and quenched by adding water. The product was extracted with EtOAc (x3) and the combined organic layers washed with brine, dried over MgS04, filtered and concentrated under vacuum. Purification by preparative HPLC gave the title compound (32 mg, 70 %) as a colourless solid. NMR (400 MHz, Me-c/3-OD): 8.36 (1 H, s), 8.24 (1 H, d), 8.08 (1 H, dd), 7.71 (1 H, dd), 4.66 (2H, s), 4.28 (2H, s), 4.1 1-4.02 (1 H, m), 4.02-3.95 (2H, m), 3.59-3.51 (2H, m), 2.05-1.97 (2H, m), 1.69-1.58 (2H, m), 1.38 (9H, s). MS: [M+H]+ = 458.
As the paragraph descriping shows that 29726-60-1 is playing an increasingly important role.
Reference£º
Patent; OTSUKA PHARMACEUTICAL CO., LTD.; BERDINI, Valerio; BUCK, Ildiko Maria; DAY, James Edward Harvey; GRIFFITHS-JONES, Charlotte Mary; HEIGHTMAN, Thomas Daniel; HOWARD, Steven; MURRAY, Christopher William; NORTON, David; O’REILLY, Marc; WOOLFORD, Alison Jo-Anne; COOKE, Michael Liam; COUSIN, David; ONIONS, Stuart Thomas; SHANNON, Jonathan Martin; WATTS, John Paul; (867 pag.)WO2017/68412; (2017); A1;,
Tetrahydroisoquinoline – Wikipedia
1,2,3,4-Tetrahydroisoquinoline | C9H11N – PubChem